The Haystack Project
  • Home
  • About Us Participants Partners Board and Advisors
  • Priorities
  • PROTECT Rare
  • Rare Disease Approvals HEART Act
  • Speaker Series Payer Engagement Health Equity Rare Cancer
  • Inflation Reduction Act Medicare Section 340b Medicaid FDA ICER
  • Patient Stories
  • Join
  • Take Action
The Haystack Project
  • Home/
  • About/
    • About Us
    • Participants
    • Partners
    • Board and Advisors
  • Priorities/
  • PROTECT Rare/
  • FDA/
    • Rare Disease Approvals
    • HEART Act
  • Programs/
    • Speaker Series
    • Payer Engagement
    • Health Equity
    • Rare Cancer
  • Policy/Comments/
    • Inflation Reduction Act
    • Medicare
    • Section 340b
    • Medicaid
    • FDA
    • ICER
  • Patient Stories/
  • Join/
  • Take Action/
Blue-Banner.png
The Haystack Project

Resources

The Haystack Project
  • Home/
  • About/
    • About Us
    • Participants
    • Partners
    • Board and Advisors
  • Priorities/
  • PROTECT Rare/
  • FDA/
    • Rare Disease Approvals
    • HEART Act
  • Programs/
    • Speaker Series
    • Payer Engagement
    • Health Equity
    • Rare Cancer
  • Policy/Comments/
    • Inflation Reduction Act
    • Medicare
    • Section 340b
    • Medicaid
    • FDA
    • ICER
  • Patient Stories/
  • Join/
  • Take Action/
April 17, 2024

Pink Sheet: Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length→

April 17, 2024/ Tiara Logan

Read here.

April 17, 2024/ Tiara Logan/ /Source
News
FDA

Tiara Logan

March 20, 2024

Haystack MPPP Pt 2 Guidance Comments 3.15.24→

March 20, 2024/ Tiara Logan

Read more.

March 20, 2024/ Tiara Logan/ /Source
Letters, Comment Letters
IRA

Tiara Logan

March 04, 2024

Haystack Part D Redesign Comments

March 04, 2024/ Tiara Logan

Read more.

March 04, 2024/ Tiara Logan/
Comment Letters, Letters
IRA

Tiara Logan

February 12, 2024

Haystack Project Support of HR 485→

February 12, 2024/ Tiara Logan

Read here.

February 12, 2024/ Tiara Logan/ /Source
Comment Letters, Letters
ICER

Tiara Logan

February 05, 2024

Pink Sheet: FDA Looking To Boost Transparency On How Patient Input Is Used In Drug Reviews→

February 05, 2024/ Tiara Logan

Read here.

February 05, 2024/ Tiara Logan/ /Source
News
FDA

Tiara Logan

January 25, 2024

RFI on Improving and Protecting Access to Gene Therapies→

January 25, 2024/ Tiara Logan

Read more.

January 25, 2024/ Tiara Logan/ /Source
Comment Letters, Letters
Medicaid, Medicare

Tiara Logan

January 24, 2024

Gene Therapy Allows an 11-Year-Old Boy to Hear for the First Time→

January 24, 2024/ Tiara Logan

Read more.

January 24, 2024/ Tiara Logan/ /Source
Patient Stories

Tiara Logan

November 15, 2023

NASEM meeting kicks off study on FDA and EMA processes for rare disease drugs→

November 15, 2023/ Tiara Logan

Read more.

November 15, 2023/ Tiara Logan/ /Source
FDA

Tiara Logan

November 10, 2023

Politico AgencyIQ Article: NASEM meeting kicks off study on FDA and EMA processes for rare disease drugs→

November 10, 2023/ Tiara Logan

Link to the article with press coverage of the meeting. See page 3 for what the reporter had to say about Haystack’s participation.

November 10, 2023/ Tiara Logan/ /Source
news, FDA

Tiara Logan

September 20, 2023

Medicare Prescription Payment Plan Guidance →

September 20, 2023/ Tiara Logan

Read more.

September 20, 2023/ Tiara Logan/ /Source
Comment Letters, Letters
IRA, Medicare

Tiara Logan

August 21, 2023

Haystack Comments on CMS Proposed Evidence Standards NCD→

August 21, 2023/ Tiara Logan

Read more.

August 21, 2023/ Tiara Logan/ /Source
Comment Letters, Letters
Medicare, Medicaid, cms

Tiara Logan

August 21, 2023

Haystack Comments CMS Proposal on CED→

August 21, 2023/ Tiara Logan

Read more.

August 21, 2023/ Tiara Logan/ /Source
Comment Letters, Letters
medicare, medcaid

Tiara Logan

August 17, 2023

Access to Rare Indications Toolkit→

August 17, 2023/ Michelle Osburn

Read more.

August 17, 2023/ Michelle Osburn/ /Source
Letters
rare

Michelle Osburn

August 17, 2023

DRAFT: Haystack expresses gratitude for the support of Representatives and the "PROTECT Act"→

August 17, 2023/ Michelle Osburn

Read more.

August 17, 2023/ Michelle Osburn/ /Source
Letters, Comment Letters
rare, protect

Michelle Osburn

August 04, 2023

Alpha Rev's Casey McPherson Gave Up a Life in Music to Cure His Daughter's Rare Disease→

August 04, 2023/ Michelle Osburn

Read more.

August 04, 2023/ Michelle Osburn/ /Source
Patient Stories
patient

Michelle Osburn

July 31, 2023

Haystack comments on CMS' Information Collection Request for Negotiation Data Elements (CMS-10847)→

July 31, 2023/ Michelle Osburn

Read more.

July 31, 2023/ Michelle Osburn/ /Source
Comment Letters, Letters
cms, icr, IRA

Michelle Osburn

July 28, 2023

Haystack's responses to the bipartisan RFI on potential refinements to the 340B drug discount program→

July 28, 2023/ Michelle Osburn

Read more.

July 28, 2023/ Michelle Osburn/ /Source
Comment Letters, Letters
RFI, drug, 340b

Michelle Osburn

July 14, 2023

These twins share everything including a rare disease and surgery on the same day→

July 14, 2023/ Michelle Osburn

Read more.

July 14, 2023/ Michelle Osburn/ /Source
Patient Stories
patient

Michelle Osburn

July 12, 2023

A young girl’s custom gene therapy hints at a framework for tailored rare disease treatments→

July 12, 2023/ Michelle Osburn

Read more.

July 12, 2023/ Michelle Osburn/ /Source
Patient Stories
patient

Michelle Osburn

July 03, 2023

Haystack's Comments on Craft of bill on State Integrated Care Programs for Dual Eligible Individuals→

July 03, 2023/ Michelle Osburn

Read more.

July 03, 2023/ Michelle Osburn/ /Source
Comment Letters, Letters
cms, medicare, Medicaid, dual-eligible

Michelle Osburn

  • Previous
  • Next

About Us

The Issues

Resources

News & Updates

© 2020 Haystack Project. All Rights Reserved. 

 

Contact Us

Please consider making a tax-deductible donation to support the Haystack Project today.

The Haystack Project is a 501(c)3 nonprofit that brings together patients organizations representing patients suffering from or caring for patients with extremely rare diseases. Our mission is to educate policymakers and other stakeholders about the need for policies that recognize the unique circumstances of extremely rare conditions and treatments and expand incentives critical to ensuring they can reach patients.